| Abstract | Autoimmune MRL/1 mice were treated with a recently developed substance with immunomodulating properties, LS-2616. Treatment was initiated at the age of 8 weeks, before the onset of clinically apparent disease, and at 16 weeks of age, after development of established lupus disease. Beneficial therapeutic effects were obtained, even when LS-2616 was administered at the lowest dose tested (1 mg/mouse/week) to 16-week-old mice. The effects of LS-2616 on longevity, as well as on development of lymphadenopathy, splenomegaly, glomerulonephritis, and vasculitis, were pronounced and were comparable with those of cyclophosphamide. The results obtained suggest a potential role for LS-2616 in the treatment of autoimmune disease in humans. |
| Authors | A Tarkowski, K Gunnarsson, L A Nilsson, L Lindholm, T Stålhandske |
| Journal | Arthritis and rheumatism
(Arthritis Rheum)
Vol. 29
Issue 11
Pg. 1405-9
(Nov 1986)
ISSN: 0004-3591 UNITED STATES |
| PMID | 3778545
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
| Chemical References |
- Adjuvants, Immunologic
- Hydroxyquinolines
- Cyclophosphamide
- roquinimex
|
| Topics |
- Adjuvants, Immunologic
(therapeutic use)
- Animals
- Autoimmune Diseases
(drug therapy, immunology, pathology)
- Cyclophosphamide
(therapeutic use)
- Drug Evaluation, Preclinical
- Female
- Glomerulonephritis
(pathology)
- Hydroxyquinolines
(therapeutic use)
- Immunity
(drug effects)
- Lymphatic Diseases
(pathology)
- Mice
- Mice, Inbred Strains
(immunology)
- Splenomegaly
(pathology)
- Vasculitis
(pathology)
|
